GlassScriptPhysician profile
Kendall N Daasnes
NPI 1720658362
$2,025.67
in general payments reported to CMS, 2019-2025
27 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.01 · 2022: $740 · 2023: $214 · 2024: $640 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,261.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $385.72 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $269.95 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $209.45 | 2022-2025 | |
| Philips North America LLC | $185.51 | 2022-2025 | (Ck4) Mcot, Extended Holter, (5044) Mcot |
| Merck Sharp & Dohme LLC | $141.83 | 2022-2025 | Gardasil 9, Capvaxive |
| Urovant Sciences INC | $124.99 | 2022 | |
| Pfizer INC. | $97.35 | 2023-2025 | |
| Esperion Therapeutics, INC. | $47.28 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.91 | 2021-2022 | |
| Verity Pharmaceuticals INC. | $44.34 | 2024-2025 | Tlando |
| Astrazeneca Pharmaceuticals LP | $44.12 | 2025 | Airsupra |
| Corcept Therapeutics | $43.54 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.74 | 2024 | Tradjenta, Jardiance |
| Glaxosmithkline, LLC. | $36.94 | 2024 | Arexvy |
| Exact Sciences Corporation | $32.63 | 2024 | Cologuard Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.08 | 2024 | Xifaxan |
| Viiv Healthcare Company | $26.64 | 2023 | Apretude |
| Alkermes, INC. | $26.31 | 2025 | Vivitrol |
| Astellas Pharma US INC | $24.93 | 2024 | Veozah |
| Dexcom, INC. | $23.83 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $23.09 | 2025 | Evenity, Prolia |
| Amarin Pharma, INC. | $22.01 | 2022 | |
| Scilex Pharmaceuticals INC. | $21.57 | 2022 | |
| Organon LLC | $21.04 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.31 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.18 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.38 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendall Daasnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.